Urinary tract infections in children: building a causal model-based decision support tool for diagnosis with domain knowledge and prospective data

Jessica A. Ramsay¹, Steven Mascaro^{2,3}, Anita J. Campbell^{1,4}, David Foley⁵, Ariel O. Mace^{1,6}, Paul Ingram^{5,7}, Meredith L. Borland^{8,9}, Christopher Blyth^{1,4,5,10}, Nicholas G. Larkins¹¹, Tim Robertson¹², Phoebe Williams^{13, 14, 15}, Tom Snelling^{1,13,14,16,17}, Yue Wu^{1,13*}

- Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Nedlands WA 6009, AU
- 2. Bayesian Intelligence Pty Ltd, Upwey VIC 3158, AU
- 3. Faculty of Information Technology, Monash University, Clayton VIC 3168, AU
- 4. Department of Infectious Diseases, Perth Children's Hospital, Nedlands WA 6009, AU
- Department of Microbiology, PathWest Laboratory Medicine WA, QEII Medical Centre, Nedlands WA 6009, AU
- 6. Department of General Paediatrics, Perth Children's Hospital, Nedlands WA 6009, AU
- School of Pathology and Laboratory Medicine, University of Western Australia, Nedlands WA 6009, AU.
- 8. Emergency Department, Perth Children's Hospital, Nedlands WA 6009, AU
- Divisions of Emergency Medicine and Paediatrics, School of Medicine, University of Western Australia, Nedlands WA 6009, AU
- 10. Faculty of Health and Medical Sciences, University of Western Australia, AU
- 11. Department of Nephrology, Perth Children's Hospital, Nedlands WA 6009, AU
- 12. Child and Adolescent Health Service, Perth Children's Hospital, Nedlands WA 6009, AU
- Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Camperdown NSW 2006, AU
- 14. Sydney Children's Hospital Network, NSW 2031, AU
- 15. School of Women's and Children's Health, The University of New South Wales, NSW 2052, AU
- 16. School of Public Health, Curtin University, Bentley WA 6102, AU
- 17. Menzies School of Health Research, Charles Darwin University, Darwin NT 0815, AU

*yue.wu1@sydney.edu.au

Abstract

Background: Diagnosing urinary tract infections (UTIs) in children in the emergency department (ED) is challenging due to the variable clinical presentations and difficulties in obtaining a urine sample free from contamination. Clinicians need to weigh a range of observations to make timely diagnostic and management decisions, a difficult task to achieve without support due to the complex interactions among relevant factors. Directed acyclic graphs (DAG) and causal Bayesian networks (BN) offer a way to explicitly outline the underlying disease, contamination and diagnostic processes, and to further make quantitative inference on the event of interest thus serving as a tool for decision support.

Methods: We prospectively collected data on children present to ED with suspected UTIs. Through knowledge elicitation workshops and one-on-one meetings, a DAG was co-developed with domain experts (the Expert DAG) to describe the causal relationships among variables relevant to paediatric UTIs. The Expert DAG was combined with prospective data and further domain knowledge to inform the development of an application-oriented BN (the Applied BN), designed to support the diagnosis of UTI. We assessed the performance of the Applied BN using quantitative and qualitative methods.

Results: We summarised patient background, clinical and laboratory characteristics of 431 episodes of suspected UTIs enrolled from May 2019 to November 2020. The Expert DAG was presented with a narrative description, elucidating how infection, specimen contamination and management pathways causally interact to form the complex picture of paediatric UTIs. Parameterised using prospective data and expert-elicited parameters, the Applied BN achieved an excellent and stable performance in predicting *E.coli* culture results, with a mean AUROC of 0.86 and a mean log loss of 0.48 based on 10-fold cross-validation. The BN predictions were reviewed via a validation workshop, and we illustrate how they can be presented for decision support using three hypothetical clinical scenarios.

Conclusion: Causal BNs created from both expert knowledge and data can integrate case-specific information to provide individual decision support during the diagnosis of paediatric UTIs in ED. The model aids the interpretation of culture results and the diagnosis of UTIs, promising the prospect of improved patient care and judicious use of antibiotics.

Key words: DAG, causal model, Bayesian network, clinical decision support, urinary tract infection

Abbreviations: UTI, ED, DAG, BN, CPT

1. Introduction

Urinary tract infections (UTIs) are a common reason for children to present to hospital emergency departments (EDs) (1,2). Diagnoses of UTIs in children are made difficult because signs and symptoms are often non-specific and poorly sensitive, especially in those too young to communicate verbally. Although urine culture is considered the gold standard for the diagnosis of UTIs, urine testing may be affected by false positive and false negative results. Sample collection is challenging and urine contamination in children is frequent and can cause false positive diagnoses or obscure true positive infections, resulting in inappropriate treatment (4). Urine testing may also be affected by false negatives due to prior use of antibiotics and low bacterial counts (3). Management of UTIs in children requires timely decisions that balance the risks of secondary bacteraemia and sepsis if appropriate treatment is delayed, and the potential side effects of those treatments, as well as the growing public health risks from antimicrobial resistance associated with indiscriminate treatment (3).

Formulating a diagnosis relies on gathering, requesting, and synthesising information from multiple sources under time and resource constraints. Cognitive heuristics (i.e. short cuts) allow decisions to be made quickly and with little information and high uncertainty; however, these heuristics may be biased and are thought to contribute to 75% of misdiagnoses (4,5). The management of children with suspected UTI in the ED could benefit from decision support based on quantitative modelling. A number of predictive models have been constructed to aid the diagnosis and management of UTIs in children, with varying success. Individual biomarkers have been proposed for guiding diagnosis (6,7), treatment and prognostication, while others propose combining routinely collected information to provide quantitative risk-based assessments (8,9). The lack of explanability and user engagement may be the reason many predictive models, regardless of their accuracy, fail to be successfully implemented or utilised (10–13). Causal directed acyclic graphs (DAGs) can be used to map and describe effects centred around a causal question of interest (14), providing a potential way to address the lack of explanability.

Causal DAGs are a graphical representation of variables of interest and their relationships with each other, depicted by a series of nodes (variables) and arrows (the causal relationships between the connected variables) (15). They assist in understanding when and how observing one variable should change our expectation of another, either because the first variable *causes* the second, the first is *caused by* the second, each is *caused by a third* variable, or because each *shares an effect* which is also observed. Bayesian network (BN) models extend DAGs by quantifying the strength and direction of the cause-effect relationships between variables using conditional probability tables (CPTs), capturing a deeper understanding of a problem (16,17). When the relationships between all relevant observable and unobservable (latent) variables are organised under a causal BN framework, observed variables (data) can then be used to make probabilistic inference about missing variables that are either unobservable and must always be inferred (e.g., latent states), or those that are potentially observable but not yet observed (e.g., future outcomes). They provide an approach for designing decision support tools by predicting unobserved variables using available data. Causal BN models can be synthesised to describe a complex problem by combining expert opinion on the qualitative structure (i.e. the DAG) with expert opinion and/or data to parameterize it (17). This approach compensates for data limitations to improve model predictions and may help to illuminate the clinical problem at hand and increase the likelihood that any decision support tools arising from these models will be used in clinical care.

Causal BN models thereby offer a way of organising information in a coherent way that captures the complex relationships amongst variables relevant to the problem domain of paediatric UTIs. Here we describe the methodological process of building a causal BN based decision support tool for diagnosing the causative pathogens for children who present to ED for suspected UTI. We illustrate how an expertelicited causal DAG can be translated into an applied BN model parameterised with a prospective paediatric cohort. We discuss the potential use of the applied BN model in clinical settings with the aim of guiding the diagnosis and management of UTI in children.

2. Methods

This project is described in three phases to illustrate how prospective cohort data (2.1) and an expertelicited causal DAG (2.2) can be utilised to derive a clinical decision support BN quantifying the strength of these relationships (2.3).

2.1 The prospective paediatric emergency department cohort

Our prospective cohort enrolled children from the ED of Western Australia's sole tertiary public children's hospital (Perth Children's Hospital). The study aimed to capture clinical and laboratory information about UTIs and their risk factors from paediatric ED clinicians, laboratory results, and from parents of children with a suspected UTI. A child was included if they were aged less than 13 years, presented to the ED with a suspected UTI, had urine collected for laboratory culture and susceptibility testing, were prescribed empiric antibiotics for their suspected UTI, and had informed consent provided by their legal guardian. Participants could be re-enrolled if they presented to the ED at least 14 days after their initial presentation. Ethics approval was granted by the Child and Adolescent Health Service Human Research Ethics Committee (EC00268).

Electronic and paper medical records were systematically reviewed to capture the participant's clinical history including their demographics, reported signs and symptoms, clinical observations, laboratory results, and treatments prescribed. Parents were surveyed at enrolment to identify any additional risks factors for antimicrobial resistance and 14 days after presenting to the ED to ascertain treatment outcomes. Samples were processed, analysed and reported by the local laboratory per their standard procedures. Additional file 1 provided a detailed schematic of the participants enrolment and data collection.

2.2 Qualitative model: the Expert DAG

A qualitative causal DAG was constructed based on knowledge elicited from local clinical experts over multiple iterations (the *Expert DAG*). The experts were chosen to represent a range of health professionals typically involved in the diagnosis and management of children with UTIs at a tertiary hospital, and therefore the intended end-users of a decision support tool resulting from this work. The experts were from paediatric emergency medicine, microbiology and infectious diseases, general paediatrics, nephrology, epidemiology and medical laboratory science.

The elicitation rested on an initial causal framework based on preliminary insights from the prospective cohort data and mixed domain and modelling knowledge from a core team (YW, JAR, SM, TS). Proposed relationships from this initial framework were then confirmed, corrected, or expanded after input from the broader expert group (DF, AJC, PI, MLB, CB, NGL, TR, AOM, PW). Many causal relationships between model variables were fairly intuitive and not controversial, meaning the relationships were clear (often visible) events occurring in clear temporal sequence. Therefore, elicitation

of the model structure occurred with moderated discussion where a full Delphi protocol was not warranted. Additionally, discussions within a diverse expert group allowed consensus to be achieved, with specialty input only requested when needed, replicating decision-making processes in clinical care.

The outcome DAG elicited from the experts was then refined by the core team and re-presented in a written format, with each causal relationship depicted explicitly described. Further iteration was sought via written feedback and one-on-one expert and core team discussions. The resultant final Expert DAG describing the diagnosis and management of UTIs in children is described in Section 3.2.

2.3 Quantitative model: the Applied BN

The final Expert DAG was converted into an application-oriented BN (the *Applied BN*), designed to illustrate how BN models can provide clinical decision support for the diagnosis and management of suspected UTI in children who present to the ED. Information from both the Expert DAG and the prospective cohort data were integrated to inform the selection of Applied BN variables. Conversion of the Expert DAG took into consideration: how a particular variable is relevant to the Applied BN's purpose; how it could be matched to available data; and how it could help simplify parameterisation or computational workload. This process frequently involved simplifications by removing and merging variables, and expansions by splitting and adding variables. All changes during the conversion ensured the structure of the Applied BN was compatible with the Expert DAG, meaning all the elicited causal relationships were preserved either by explicit causal links or, where it was considered necessary, non-causal approximations.

The Applied BN was parameterised using data from the prospective cohort. In many cases, a variable's probability conditional on its parents (predecessor node) could be estimated directly from the data. However, some of the variables in the Applied BN are latent, as they play crucial explanatory or simplification roles, and parameterisation in such cases is less straightforward. There are two kinds of latent parameters associated with latent variables: parameters that quantify the relationship of the latent variable with its parents; and parameters that quantify the relationship of the latent variable with its parents; and parameters that quantify the relationship of the latent variable with its children (nodes extending from other nodes). In most cases, latent parameters were handled by eliciting estimated probabilities from experts and using these estimates as seeds to the expectation maximisation (EM) algorithm (18). Specifically, parameterisation surveys were created and issued to experts to elicit parameters for all latent variables and these parameters were used to inform the corresponding CPTs. In most cases, these CPTs constituted priors that were further updated by the prospective cohort data, while in other cases, the CPTs were kept fixed. In addition, one group of latent parameters were determined separately, making use of EM in the form of a clustering algorithm to "complete" the data (see Section 3.3 for description). Additional file 2 includes the full list of survey questions used to elicit parameters for the Applied BN.

The Applied BN was evaluated from the perspective of both (numerical) accuracy and clinical usefulness. BN predictions for a selected set of target variables (e.g., pathogen-specific urine culture results) were compared with the observations of those variables captured in the prospective cohort study. The difference between the BN predictions and observations were described using two metrics based on 10fold cross-validation, namely the area under the receiver-operator curve (AUROC) and the log loss (19), both intended to measure the performance characteristics of the model, though each in different ways. A sensitivity analysis was conducted on the conditional probability parameters with a high degree of uncertainty, using variance-based sensitivity analysis (VBSA) (20,21). VBSA allows the distribution of several input parameters to be investigated simultaneously to help understand how changes influence the

BN target predictions in the CPTs. The clinical experts evaluated the clinical usefulness of the BN via a validation workshop where relationships and concepts were checked and refined. Three scenarios were simulated to demonstrate how the Applied BN might be used for clinical decision support for a child presenting to the ED with a suspected UTI.

3. Results

3.1 Prospective paediatric cohort

From May 2019 to November 2020, 391 children were enrolled in the prospective cohort study. This accounted for 431 UTI episodes, where the mean age at presentation was 3.9 years old (Interquartile Range, IQR, 0.7 - 6.2) and 316 (73%) were girls. A prior history of UTI or urinary tract pathology (e.g., neuropathic bladder, phimosis, renal agenesis, dysplasia) were reported in 197 (46%) of participants according to their medical notes or reported by their parent in the study survey. Commonly reported symptoms on ED presentation included parent-reported fever (269, 62%), nausea and/or vomiting (169, 39%), poor oral intake (161, 37%), abdominal pain (144, 33%), and pain or discomfort referrable to the urinary tract (148, 34%). Symptoms varied significantly between those < 2 years old and those > 2 years old (Table 1). Children were prescribed antibiotics during their episode of care as per the inclusion criteria, where broad spectrum¹ antibiotics were prescribed in 32% of children. Among the 431 urine samples collected in the ED, 219 (51%) reported pure growth, 150 (35%) reported no growth and 7 (2%) reported mixed growth, while urine culture data was unavailable for 56 episodes (13%). Escherichia coli (E.coli) was the most common bacteria reported accounting for 204 (47%) of total episodes and 90% of positive urine samples (204/226). Other Gram negative organisms (e.g. Proteus mirabilis, Enterobacter cloacae, Pseudomonas aeruginosa) and Gram positive organisms (e.g. Staphylococcus aureus, Enterococcus faecalis) were isolated in 4% and 3% of total episodes, attributing to 7% (16/226) and 6% (13/226) of positive samples, respectively. Antibiotic use prior to ED presentation was reported in 61 (14%) of episodes and was negatively associated with urine culture (Table 1).

Table 1. Prospective cohort study summary statistics. Unless stated otherwise, all percentages were calculated using positively reported observations within each age group (i.e., as a percentage of the 179 cases for <2yo, and 252 cases for >=2yo). Of note, when a variable (e.g., abdominal pain) was not reported, it's likely that the child reported no pain (confirmed negative observation) or the data was missing (e.g., not queried or recorded by the treating doctors).

Subgroup by age group	<2yo 179 (41.5% of total 431 episodes)	>=2yo 252 (58.5% of total 431 episodes)				
Female	101 (56%)	215 (85%)				
Prior urinary tract pathology (including previous UTI)	55 (31%)	142 (56%)				
On antibiotics at ED presentation ¹						
Broad	6 (3%)	14 (6%)				
Narrow	15 (8%)	26 (10%)				

Demographics and clinical history

¹ The specified antibiotic was classified as narrow (<=3) or broader (>3) according to published Antibiotic Spectrum Index (22). Narrow: Amoxicilin, Trimethoprim, Benzylpenicillin, Cefalexin, Cefazolin, Erythromicin. Broad: Amoxicillin + Clavulanic acid, Trimethoprim + Sulfamethoxazole, Co-trimoxazole, Amikacin, Cefepime, Cefotaxime, Ceftazidime, Ceftriaxone, Ciprofloxacin, Colistin, Ertapenem, Gentamicin, Meropenem, Moxifloxacin, Nitrofurantoin, Norfloxacin, Piperacillin + Tazobactam, Tobramycin, Vancomycin

Clinical symptoms recorded		
Pain or discomfort referrable to the urinary tract (e.g., dysuria, genital pain)	11 (6%)	137 (54%)
Parent reported fever	137 (77%)	132 (52%)
Temperature >38°C	43 (24%)	64 (25%)
Abdominal pain	5 (3%)	139 (55%)
Foul smelling urine	34 (19%)	27 (11%)
Haematuria	6(3%)	17 (7%)
Irritable	72 (37%)	19 (8%)
Lethargy	52 (29%)	51 (20%)
Nausea/vomiting	76 (42%)	93 (37%)
Poor oral intake	85 (47%)	76 (30%)
Diarrhoea	25 (14%)	12 (5%)
Respiratory symptoms	46 (26%)	43 (17%)
ED Investigations and management red	corded	
C-reactive protein		
$\geq 15 \text{ mg/L}$	49 (27%)	29 (12%)
Investigation not done	108 (60%)	206 (82%)
Leucocyte count	57 (2000)	20 (120)
≥10 x10^9/L	57(32%)	30(12%)
Investigation not done	109 (81%)	209 (85%)
Neutrophin count $>8 \times 10^{0/7}$	26(15%)	28(110)
≥8 x 10 9/L Investigation not dona	20(15%) 100(61%)	20(11%) 200(83%)
Broad spactrum ¹ antibiotic ampirically	57 (32%)	209(83%)
prescribed	57 (5270)	82 (55%)
Patients discharged after ED consult	108 (60%)	217 (86%)
Urine analysis		
	1	
Method of urine specimen collection		
Clean catch	63 (35%)	112 (44%)
Catheter	70 (39%)	16 (6%)
Suprapubic aspirate	2(1%)	
Bacteria seen on microscopy	110 (66%)	94 (37%)
>100 leucocytes per high power field	107 (60%)	145 (57%)
Moderate epithelial cells on microscopy	21 (12%)	32 (13%)
Leucocyte esterase (3+) on urine dipstick	51 (28%)	
Nitrites detected on urine dipstick	64 (36%)	76 (30%)
Urine culture	1	
No growth	47 (26%)	103 (41%)
E.coli	97 (54%)	107 (42%)
Gram-negative bacteria (other than <i>E.coli</i>)	6 (3%)	10 (4%)
Gram-positive bacteria	5 (3%)	8 (3%)
Subgroup by antibiotics use prior to ED	On antibiotic 61 (14%, n=431)	Not on antibiotic 342 (79%, n=431)
No growth	35 (57%, n=61)	106 (31%, n=342)
E.coli	13 (21%, n=61)	177 (52%, n=342)
Gram-negative bacteria (other than <i>E.coli</i>)	4 (7%, n=61)	11 (3%, n=342)
Gram-positive bacteria	2 (3%, n=61)	11 (3%, n=342)

3.2 Expert DAG description

The Expert DAG comprising 29 variables represents a mechanistic causal model of UTI infection, diagnosis and management of children presenting to an ED (Figure 1). A detailed variable dictionary for the Expert DAG is provided in Additional file 3. The model can be divided into the infection, contamination, and management pathways.



Figure 1. The Expert DAG v11.1. The expert-elicited causal directed acyclic graph describing the relationships between infection (white), specimen contamination (yellow) and UTI management (purple) in children, in particular, variables that fell into more than one pathways were indicated in green. Note: Numbers within the model nodes correspond with the narrative description. A detailed variable dictionary is provided with the supplementary material: Additional file 3. The source model file for the Expert DAG can be accessed via https://osf.io/8taqy/.

The Infection Pathway

The infection pathway describes predisposing background factors and the pathophysiology of infection, and how a UTI gives rise to signs, symptoms and laboratory evidence. For a UTI to occur, organisms must be present in the urinary tract (d13), usually from ascension of organisms from the external genitalia (d12) or, on rare occasions, from haematogenous seeding of the upper urinary tract with organisms from the bloodstream (d14) which then infect the urinary tract (d15) (23). Infection here is a 'latent' event, meaning that although it may be inferred from evidence with varying confidence, it generally cannot be directly observed; importantly we separate the *existence* of a *UTI* (infection pathway, d15), from the *diagnosis* of a *suspected UTI* (management pathway, d2) based on the presence or absence of various

signs, symptoms, dipstick test and laboratory results. Age and UTI-relevant comorbidities (such as structural or functional abnormalities of the urinary tract) influence the probability of a UTI in a given child, due to their predisposing effect (24). Infection of the urinary tract typically provokes an inflammatory response which may manifest as UTI-localising signs and symptoms (d17) caused by inflammation of the urinary tract, and/or non-localising signs and symptoms (d16) caused by systemic inflammation. In children, especially those too young to communicate verbally, UTI-localising symptoms may be difficult to ascertain, forcing clinicians to assess observable signs and symptoms that are non-specific and non-localising such as fever and irritability, and which are shared with other conditions (25). Where incompatible signs and symptoms (d18) are present - those not typically associated with a UTI (e.g., respiratory symptoms), the diagnosis is dependent on the probability of alternative diagnoses that may provide a better explanation for the child's presentation.

The Contamination Pathway

The practical definition of urinary contamination varies widely across the literature and in practice (26,27). Contamination and infection are often considered mutually exclusive, but in reality organisms cultured from urine samples may be pathogens, contaminants, or both. In our model, contamination is treated as a latent event, and describes the presence of non-causative organisms in a urine specimen (d28). Contamination usually occurs at the time of collection when organisms present superficially on the external genital area (d12) become mixed with the 'clean' urine sample from the bladder (in this context, 'clean' means the specimen is free from contaminants, not that it is free of organisms). A child's age, sex, and for boys, circumcision status, can directly influence both the density of any organisms present on the external genitalia (d12) and the ability to produce a clean urine sample (d24). Incontinence and/or diarrhoea may increase the density of organisms present on the external genitalia (d12), increasing the risk of specimen contamination (d27), and possibly also the risk of infection of the urinary tract (d15) via the ascending route (d12).

The probability of contamination is strongly influenced by the urine collection method (d3). Within the model, the latent concept of specimen contamination risk (d27) represents all factors contributing to contamination which, if true, increases the probability of the presence of non-causative organism in the specimen (d28). Laboratory processing factors (d26) representing any process that may introduce (rare in most laboratories) or concentrate non-causative organisms in the specimen (d28) from when the urine arrives in the laboratory to its final reporting. This may include delays in sample processing or refrigeration and improper aseptic technique.

The Management Pathway

The existence of a UTI cannot be known with absolute certainty, and a clinician's belief (or judgement) about its presence or absence may vary over time, perhaps related to evolving evidence. It may be suspected on the clinician's initial assessment (d1) based on the child's history and background risk factors. As more evidence is gained via the elicitation of symptoms and signs and from investigations, a working or provisional diagnosis of UTI is made (d2) – thus, the suspicion based on the initial assessment (d1) is updated. A urine specimen may be sent to the laboratory (d4) and if the suspicion of UTI is sufficiently high, empiric antibiotics may be prescribed (d5) even before the urine testing results are known. Management decisions are also influenced by whether the clinician believes that there is a high risk of the patient having or developing complications (d22). In the model, this is represented as a latent concept that describes the risk of progressing to severe complications. This risk is largely driven by a

child's age, the time delay to seeking and/or initiating treatment, and the presence of comorbidities such as abnormalities of the urinary tract or immune system.

Interpretation of the presence, type and density of growth cultured from a urine specimen (d7) is difficult, as this is where the contamination and infection pathways converge. Information regarding these pathways is not normally available to the laboratory scientist deciding how to report the results (d8) of the urine test. Thus, if an organism is isolated with evidence of an inflammatory response (e.g. pyuria) on microscopic analysis (d6), the probability that the cultured organism is causative is high and therefore it is reported as significant in the laboratory report (d8) and antimicrobial susceptibility results are also reported. In contrast, the isolation of multiple organisms is typically reported as a 'mixed growth', precluding either the confirmation or exclusion of a UTI.

A final updated clinical diagnosis (d9) is made when outstanding evidence or other information is available. The existence of a UTI directly influences the urine laboratory report (d8), any biomarker (d20) and imaging results (d21), as well as the subsequent clinical progress of the child (d23) with or without antibiotic treatment. A clinician uses these observations to further update their belief about the probability that the patient has a UTI, together with any antimicrobial susceptibility data from the laboratory report (d8) to decide whether to initiate, stop or change the antibiotic prescription (d10).

3.3 Applied BN for decision support

The Applied BN represents a demonstrative decision support tool using the Expert DAG that aims to help determine if a child truly has a UTI and if so, the likely causative pathogen. To develop this BN, variables in the Expert DAG were mapped to available data from the prospective cohort. Conversion of the Expert DAG into the Applied BN required simplification and expansion, whilst ensuring compatibility and preservation of the causal knowledge. Illustrative steps are summarised along the top of Figure 2. In this example, a fragment of the Expert DAG is selected (step a) that describes the presence or colonisation of bacterial pathogens on the external genitalia and in the urinary tract using two variables (d12 and d13), with an arc between them indicating that pathogens may spread from the genitalia to the urinary tract. In addition, there is depicted another possible (albeit uncommon) pathway for a pathogen to reach the urinary tract haematogenously via the bloodstream (d14). For simplicity, d14 was removed, and since this left only one explicit pathway, d12 and d13 were combined into a single variable that broadly describes local colonisation (step b). The local colonisation variable was then expanded (step c) into three nodes (b7-9) to describe local colonisation for three specific pathogen groups which are of key interest and that not only affect the probability of developing UTI, but may also constitute the causative pathogen if UTI is present (b10). Variable states were then selected (step d), typically to match the data where possible. However, in the case of latent states, this was not possible and the goal instead was to represent key divisions within each variable while minimising the demand on the latent parameterisation process. Here, each local colonisation variable is latent and has been assigned two states (High and Low), with the causative pathogen variable being assigned four states (one state for each possible causative pathogen plus a state for no pathogen/no UTI). The causative pathogen was assumed to be singular and mutually exclusive, i.e., assuming no co-infection of the urinary tract by two or more pathogens. Additional file 4 includes a full list of differences between the two models.



Figure 2. Top: An example of converting from the Expert DAG v11.1 to the Applied BN v2.2. Bottom: The high-level Applied BN structure. Additional file 4 includes a full list of differences between the two models. Additional file 5 presents the detailed structure of the Applied BN, in particular the local structure of submodels microscopic analysis, dipstick results, blood markers, and signs and symptoms (round box in the bottom panel), as well as the BN variable dictionary. The source model file for the Applied BN can be accessed via https://osf.io/8taqy/.

The Applied BN (Figure 2, bottom panel) comprises 36 nodes including 6 latent nodes, which can all be mapped to variables in the Expert DAG (see Additional file 4). Expert survey responses were collated (Additional file 6) to inform the CPT priors for the BN, which were further updated by training based on the prospective cohort data (as described in Section 2.3). Of note, the node 'current clinical phenotype' was introduced into the Applied BN as a summary node of patient presentation phenotypes after feedback from the expert validation workshop. This node is latent but was treated uniquely to provide a definition of current clinical phenotype that is independent of other latent factors in the model. In particular, a separate clustering was performed (using the EM algorithm) on the signs and symptoms, resulting in a grouping into three types, simply called "Type 1", "Type 2" and "Type 3", "Type 1" being systemic signs and symptoms predominant but mild urinary tract localising symptoms, "Type 2" being urinary tract localising symptoms. The clustering model was then used to determine each patient's most probable clinical phenotype, and this information was added to the prospective cohort data in the form of an additional column and subsequently treated like an observed variable.

It is important to reiterate, by UTI, we mean the *existence* of UTI, which reflects the state of the world where a child's urinary tract is infected by a pathogenic organism, and is only imprecisely defined. As a result, operational definitions of UTI and its causative pathogen vary across studies, and the definition is often incomplete (missing cases that we want to classify as UTIs). Evidence for UTI is indirect and comes from factors like cultures results and expert judgements, which is the way we approached it with our BN, leaving UTI as a latent variable and defined by its relationship with these other factors. The primary BN output is the **causative pathogen for UTI** (b10). Results from a 10-fold cross-validation show that the model predicts 68.0% of the presenting episodes in our cohort were UTIs, with IQR 67.2-68.9%. Specifically, this includes 40.2% E.coli UTI (IQR 39.3-40.8%), 11.6% other Gram negative UTI (IQR 11.6-11.9%), and 16.3% Gram positive UTI (IQR 14.9-18.0%). Figure 3 presents the Applied BN predictions for *E.coli* culture for every presenting episode, and compares these against their final laboratory results. The graphs represent four scenarios (a-d), each providing more information to the model than its preceding scenario. Namely, (a) provides the model with information on basic demographics (age and sex) and clinical history (history of urinary tract pathology), (b) provides (a) plus reported signs and symptoms, (c) provides (b) plus urine collection method and dipstick results, and (d) provides (c) plus all other available results (including urine microscopy and other clinical *investigations*). The evaluation results show that the evaluation metrics (log loss and AUROC) improve as more evidence is available for a given child, especially if that evidence is sensitive and/or specific for UTI.



Figure 3. Applied BN v2.2 performance as compared with observations, with Log Loss and AUROC across four scenarios. Each panel presented the distribution of the Applied BN predicted probabilities of

isolating *E.coli* from urine sample given available patient's information under the specified scenario. The predicted probabilities were compared with the reported culture result of each patient, where brown, blue and grey indicated *E.coli* was isolated, not isolated and no data, respectively. Scenario (a): age, sex, history of UTI, urinary tract comorbidities. Scenario (b): scenario (a) + reported diarrhoea, urine tract pain or discomfort, abdominal pain, haematuria, foul smelling urine, respiratory symptoms, parent reported fever, temperature, irritability, lethargy, nausea/vomiting, poor oral intake. Scenario (c): scenario (b) + urine collection methods, urine dipstick results (leucocyte esterase & nitrite). Scenario (d): scenario (c) + urine microscopy (leucocytes, bacteria, epithelial cells), leucocyte and neutrophil count (from full blood count), C-reactive protein level and ultrasound result.

Two sets of parameters turned out to be very important in driving the primary target of the Applied BN (i.e., Causative pathogen, b10), namely, the probability of UTI in the prospective cohort (i.e., one minus the probability that Causative pathogen is none) and the pathogenicity (i.e., likelihood of causing disease and worsening illness) for each organism. Understanding the proportion of UTI and the pathogenicity of different organism groups is key as they determine how often a child would acquire UTI given local colonisation of an organism that is potentially pathogenic, which organism is more likely to be the causative pathogen when two or more organism groups co-colonise, and how likely the child would manifest as a more severe clinical case. These parameters were challenging to estimate as they were completely latent, hence we relied on expert opinion collected via a parameter survey as described earlier (Section 2.3). For the first of these parameters, the survey responses gave a mean estimate of 68% UTI among the study cohort (IOR 59-81%). Table 2 presents the survey outcomes for the second set of parameters on pathogenicity for each organism. We defined the pathogenicity of an organism as the propensity of the organism to cause UTI when an otherwise healthy child is colonised by that organism on the perineum or external genitalia. The survey elicited the pathogenicity of other Gram negative and Gram positive organisms as a numerical ratio relative to *E. coli*, on average, the responses suggest that *E.coli* and gram positive bacteria are very similar regarding their pathogenicity (1 and 0.98 respectively), and the other Gram negative bacteria is the most pathogenic (scored 1.35). Unlike other responses in the survey, the elicited responses for pathogenicity varied widely among experts. In Additional file 6, we provide a summary of responses to all survey questions.

Pathogenicity	Average	SD	Expert 1	Expert 2	Expert 3	Expert 4	Expert 5	Expert 6	Expert 7	Expert 8
E.coli	1	0	1	1	1	1	1	1	1	1
Other Gram negatives	1.35	0.53	1.5	2	0.8	1	0.75	1.75	1	2
Gram positives (e.g.,										
Enterococcus)	0.98	0.91	0.5	0.2	0.5	1	0.375	2.75	0.5	2

Table 2. Expert survey outcome results of organism pathogenicity.

Given the high level of variation in these survey outcomes, we therefore conducted sensitivity analyses by varying the prior CPT parameters for b10 by $\pm 20\%$. In response, as shown in Figure 4, the predicted probability of UTI in our cohort of suspected UTIs ranged from 44 to 87%. *E.coli* is always predicted to be the most likely causative pathogen among the UTIs (39-64%), the relative attribution of other Gram negatives and Gram positives as the causative pathogen among the UTIs is sensitive to their pathogenicity, ranging from 12-29% and 22-32%, respectively.



Figure 4. Sensitivity analysis on causative pathogens as the pathogenicity of different organism changes by $\pm 20\%$.

Figures 5-7 present three hypothetical clinical scenarios to illustrate how the Applied BN may be used for point of care decision support in the management of children with a suspected UTI. Predictions for each of the scenarios is shown branching conditional on various potential information and test results as they may become available over time. The scenario in Figure 5 presents an infant who is unable to communicate any localising symptoms. As information from the dipstick test, blood test and culture result become available, the BN's predictions for the presence of UTI (and, if present, the associated causative pathogen) are updated accordingly. For example, when evidence from a dipstick result and CRP analysis are strongly indicative of UTI (i.e., "Nitrites detected" and "CRP 80"), a negative culture won't exclude a UTI. Figure 6 presents a scenario in which UTI is always highly probable. Here, the presence or absence of comorbidities, temperature, dipstick nitrites and blood neutrophil levels only influence which causative pathogen is most likely. Finally, Figure 7 describes a child with no obvious localising symptoms, where a combination of test results can both rule in or rule out a UTI, as well as affect conclusions about the most likely causative pathogen.



Figure 5. Predictions from the Applied BN under the clinical scenario A.



Figure 6. Predictions from the Applied BN under the clinical scenario B.



Figure 7. Predictions from the Applied BN under the clinical scenario C.

4. Discussion

Diagnosis and management of UTIs in children can be challenging due to the variability of clinical presentations and difficulties in obtaining a urine sample free from contamination. By mapping the causal pathways involved in this process through the development of an expert knowledge-derived DAG (the *Expert DAG*, Figure 1 & Additional file 3), we have highlighted how the convergence of the causal pathways through sample collection and clinical diagnosis are key in creating this diagnostic challenge. Further to this, we have described which information may be available at different stages of the diagnostic and management process, and which additional evidence may be required to better understand the causal process. With the data collected from 431 episodes of suspected UTI in children, we converted the Expert DAG into a causal Applied Bayesian network model (the *Applied BN*, Figure 2 & Additional file 5) to assess the probability of UTI (and if so the causative pathogen) among children with a suspected UTI.

The Applied BN achieved an excellent and stable performance in predicting *E. coli* culture results, with a mean AUROC of 0.86 and a mean log loss of 0.48 based on 10-fold cross-validation. We illustrated how the Applied BN could be implemented in practice as a clinical decision support tool using three hypothetical clinical scenarios.

4.1 The need for a better understanding of epidemiology and diagnosis of UTI

UTI epidemiology is primarily described based on urine culture results which are influenced by three causal pathways; (i) specimen contamination, where bacteria are introduced and not causative of the infection, (ii) clinical management, where empiric antibiotic exposure may suppress the bacteria causing an infection and/or specimen contamination, and (iii) the pathogenic causative organism of interest. Among the 431 episodes of suspected UTIs enrolled through the prospective cohort, after excluding 55 missing culture results, 60% specified growth of a bacterial organism, of which 90%, 7% and 6% were *E. coli*, other Gram negative bacteria and Gram positive bacteria, respectively. After the cohort data was used to train the Applied BN and thus interpreted under a causal framework, 69% of the study cohort were predicted to be UTIs, of which 57%, 16% and 27% were predicted to have been caused by *E. coli*, other Gram negatives, and Gram positive bacteria, respectively. The difference in the predicted distribution of causative pathogens by the causal model and crude microbiology data, which does not account for contamination and the effect of prior treatment, could have implications for antibiotic guidelines and urine culture reporting protocols.

More explicitly, the observed proportion of *E.coli* culture (54% of the overall prospective cohort) does not include all and only cases of UTI. The Applied BN suggests that: (i) specimen contamination results in 26% of urine culture isolates of *E.coli* being predicted to be non-UTIs and non-*E.coli* UTIs (i.e., false positives); and (ii) 84% of predicted *E.coli* UTIs reported growth of *E.coli*, implying a 16% false negative rate with a predicted 73% of prior antibiotic use. This concept is further described in the illustrative scenario of Figure 5, where for an irritable infant boy with fever and antibiotic use prior to ED, having no nitrites detected on urinary dipstick and with no CRP test performed, and where *E. coli* uTI. In contrast, for the same child with nitrites detected on their urinary dipstick and with a CRP of 80 mg/L, the Applied BN predicts a 77% chance of a *E. coli* UTI, even if *E. coli* is not isolated from the urine sample.

When making decisions, clinicians are required to balance the risks associated with treatment based on a positive urine culture result that may not represent a UTI, against the risk of complications if UTIs are not adequately treated, particularly in neonates and young infants. By organising observable information within a causal DAG, we can highlight potential mediators, confounders and sources of selection bias and measurement errors (28). The prospective cohort study has mapped out the variation in the clinical picture of children investigated for a suspected UTI. Reported symptoms and urine analysis results differed greatly with age (Table 1), which likely represents an amalgam of children with and without UTI, and further highlights the need for decision support tools to distinguish between these groups. Mapping observable variables of the prospective cohort study cohort to the variables described in the Expert DAG, coupled with simplification and expansion, has enabled a quantitative model to be developed into a decision support tool (the Applied BN). Interpreting the observations available to clinicians under this causal framework may offer a clearer understanding of the clinical picture and provide robust assessments of the likelihood of UTI.

Organism-specific pathogenicity needs to be better understood to improve the diagnosis of the causative pathogen for each UTI. Based on our experts' survey responses (Table 2), we assumed that non-*E. coli*

Gram negative bacteria have the greatest pathogenicity in the current model, while *E.coli* and Gram positive pathogens have similar and lower pathogenicity. These assumptions can have implications for the model predictions. An example can be found in the scenario of Figure 6, where, for a 3-year-old girl with reported abdominal pain, smelly urine, burning, no parent reported fever but a recorded temperature of 38 degrees, nitrites not detected on urinary dipstick and blood neutrophil count of 5×10^{9} /L, the Applied BN predicts other Gram negative bacteria as the most likely causative pathogen, regardless of whether the child has any history of urinary tract pathology. However, the survey outcomes indicated a high level of variation regarding the relative expert-derived pathogenicity of different organism groups. This was especially relevant for Gram positive organisms where growth is often attributed to contamination and the ability of some organisms to cause UTI may be disputed. As a result, the Applied BN only demonstrates there is a potential to differentiate causative pathogens for UTI like non-*E.coli* Gram negative and Gram positive bacteria, based on assumed pathogenicity and current data. While it's not yet ready to be used for differentiating pathogens, it does suggest a way forward in understanding the organism-specific pathogenicity.

4.2 Learnings from the modelling process

The Expert DAG demonstrated that specimen contamination risk, propensity to develop complications and an organism invading the urinary tract system were the key latent concepts that concerned clinical teams. Importantly, superficial colonisation of the perineum/ genitalia lies on the causal pathways mediating both invasion of the urinary tract system and specimen contamination which converge at urine culture, the only point at which either of the two pathways is typically observed. We therefore chose to model these variables explicitly in the Applied BN as pathogen-specific 'local colonisation' (b7-b9), 'causative pathogen' for UTI (b10) and 'specimen contamination risk' (b13), despite the challenges of parameterising these latent nodes. We addressed this challenge by designing survey questions to elicit estimates of relevant parameters from the domain experts. In some cases, even those expert elicited responses were inconclusive (namely, the organism-specific pathogenicity) and in those cases we conducted sensitivity analyses to ensure the implications and limitations of the uncertain parameters were recognised (as discussed for pathogenicity in the previous section).

Where possible, the Expert DAG was causal and comprehensive of the problem domain rather than constrained by variable observability or data availability. This allowed it to be used as an accurate representation of expert knowledge, enabling the use, adaptation and extension by the core research team and external researcher. By documenting the detailed steps of the conversion from the Expert DAG to the Applied BN (Additional file 4), we established a methodological framework that can be generalised beyond the UTI problem domain. Decisions to keep, remove or add variables in the applied model should be driven by a well-defined modelling purpose, matched to the availability and quality of data, and technical efficiency (such as reducing the number of latent nodes, or reducing the complexity of the variable relationships).

Like most complex modelling work, our variable selection, structure development, parameterisation and evaluation processes were iterative. The communication between modellers and the domain experts played an important role in this project, which required both parties to make efforts to understand each other's expertise and language. Medical education focuses on the pathophysiology of disease, where factor 'X' predisposes to outcome 'Y'. However, in practice, clinicians are more experienced in using rule-based flow charts and decision trees to aid in management, which depict 'if [specific signs and symptoms], then perform [this test]; if [this result] then commence [this treatment]'. The creation of an

expert-derived DAG required clinicians not only to revisit the concepts of the causal effects of each variable and their direct influence on another, but also to depart from the concept of a graph reflecting a sequence of steps or yes/no questions to observations, and instead that one may have the real outcome of interest (e.g. the *existence* of UTI) existing as a latent node in the body of the model, influencing the observable nodes that appear below it. Similarly, the concept of a latent node was challenging, given that clinicians typically work on the premise that they have the correct (i.e., 'true') diagnosis that informs their treatment decisions. While clinicians are certainly familiar with the related concepts of false positives and negatives, the extension to latent nodes was not straightforward and required more guidance from the core research team. The creation of a DAG highlights the fact that some important variables will always remain unobserved and therefore uncertain; although evidence may be accumulated to increase certainty about the presence or absence of infection, in reality infection can only ever be inferred and never directly observed. Becoming comfortable with these concepts enabled the experts to create the elicited DAG and understand its utility in clinical practice in the form of a BN.

4.3 Study limitations and future research

The prospective study cohort aimed to describe participants <13 years of age who presented into the ED and were prescribed antibiotics for a suspected UTI. With these criteria the data used to develop the models and resultant models likely represents patients that have more severe and complex disease and a greater risk of hospitalisation and antimicrobial resistance than those presenting for a UTI within the community. In other words, selection bias may be generated at the time patients were screened for eligibility and recruited for data collection, limiting the use of the Applied BN to the same cohort. Microbiology data obtained as part of the prospective study cohort was limited. The distribution of pathogens was likely representative, however, there were a small number of samples that isolated non-*E*. *coli* Gram negative bacteria and Gram positive bacteria. This required a broad pathogen grouping which may have included bacteria with greatly differing uropathogenic characteristics, as a result, only a limited understanding of how clinical and laboratory variables can help differentiate causative pathogens was developed. Further to this, a greater understanding of colonisation, infection and bacteria specific pathogenicity in the urinary tract is required to further the development of this model, yet much of this information is debated widely in the scientific community (29). The Applied BN briefly describes the empiric antibiotic prescribing patterns within the ED where 62% and 38% of described antibiotics prescriptions were narrow and broad spectrum, respectively. It is intended this model will be expanded with additional information on antimicrobial susceptibility profiles to evaluate the appropriateness of empiric antibiotic prescriptions for a range of causative pathogens.

With a richer dataset, our models could benefit from further development that could provide predictions for a broader scope, for example, incorporating how decisions were made on collecting urines and conducting blood tests, as well as potential other diagnoses other than UTI. We provide this model in its current updatable form for further parameterisation, validation, and extension by external and future researchers. The model can be adapted across a range of laboratories, hospitals and patient populations, and we anticipate this framework will aid the interpretation of culture results, the diagnosis of UTIs, and choice of antibiotic prescription, and can be incorporated into routine clinical pathways with the overall goal of improving patient outcomes and reducing inappropriate antibiotic use in children. To our knowledge this is the first causal BN for UTIs in children; we believe it serves as an exemplar for the creation and use of causal model-based decision support tools across a broad range of infectious disease problems.

Supplementary material

Additional file 1: Schematic of participant enrolment and data collection Additional file 2: Parameterisation survey questions Additional file 3: The Expert DAG variable dictionary Additional file 4: List of changes when converting the Expert DAG to the Applied BN Additional file 5: Full structure of the Applied BN and the BN dictionary Additional file 6: Parameterisation survey responses.

Declarations

Ethics approval and consent to participate Ethics approval was granted by the Child and Adolescent Health Service Human Research Ethics Committee (EC00268). Informed consent was provided by the legal guardian of each participant.

Consent for publication All authors provided consent for the publication of this work.

Availability of data and materials All source models and associated dictionaries are accessible as additional files to the manuscript, and via our Open Science Framework page, <u>https://osf.io/8taqy/</u>.

Competing interests All authors declared no competing interests.

Funding This work is supported by the Perth Children's Hospital Foundation Project grant (2018). YW is supported by the Western Australian Health Translation Network Early Career Fellowship and the Australian Government's Medical Research Future Fund (MRFF) as part of the Rapid Applied Research Translation program. AOM is supported by a National Health and Medical Research Council Postgraduate Scholarship (1191465) and an Australian Government Research Training Program Fees Offset. TS is supported by a Career Development Fellowship from the National Health and Medical Research Council (GNT1111657).

Authors' contributions TS and YW initiated the project. YW designed the project. JAR, AJC, DF and TR led the data collection. YW and JAR led data analysis and interpretation. YW, SM, JAR and TS led the DAG development. SM and YW lead the knowledge elicitation and the BN modelling, and model evaluation activities. TS, AJC, DF, AOM, PI, MLB, CB, NGL, TR and PW participated in the development of models as domain experts. JAR and YW lead the manuscript writing, and TS, SM and AOM substantially contributed to the writing. All authors have contributed to the writing and reviewed and approved the final manuscript submission.

Acknowledgements We acknowledge all enrolled participants and their family for contributing data to this research. We acknowledge research nurses Sharon O'Brien, Lisa Properjohn, Mel Dowd, Katy Whitten and Jacq Noonan at Perth Children's Hospital, emergency department for data collection.

References

- 1. Hellström A, Hanson E, Hansson S, Hjälmås K, Jodal U. Association between urinary symptoms at 7 years old and previous urinary tract infection. Arch Dis Child. 1991 Feb;66(2):232–4.
- Sood A, Penna FJ, Eleswarapu S, Pucheril D, Weaver J, Abd-El-Barr AER, et al. Incidence, admission rates, and economic burden of pediatric emergency department visits for urinary tract infection: data from the nationwide emergency department sample, 2006 to 2011. J Pediatr Urol. 2015 Oct;11(5):246.e1-8.
- 3. Kutasy B, Coyle D, Fossum M. Urinary Tract Infection in Children: Management in the Era of Antibiotic Resistance-A Pediatric Urologist's View. Eur Urol Focus. 2017 Apr;3(2–3):207–11.
- 4. Graber ML, Franklin N, Gordon R. Diagnostic Error in Internal Medicine. Archives of Internal Medicine. 2005 Jul 11;165(13):1493–9.
- 5. Kassirer JP, Kopelman RI. Cognitive errors in diagnosis: instantiation, classification, and consequences. Am J Med. 1989 Apr;86(4):433–41.
- 6. Ünsal H, Kaman A, Tanır G. Relationship between urinalysis findings and responsible pathogens in children with urinary tract infections. J Pediatr Urol. 2019 Dec;15(6):606.e1-606.e6.
- Gorczyca D, Augustyniak D, Basiewicz-Worsztynowicz B, Karnas-Kalemba W. Serum and urinary MIP-1α and IP-10 levels in children with urinary tract infections. Adv Clin Exp Med. 2014 Dec;23(6):933–8.
- 8. Kuppermann N, Dayan PS, Levine DA, Vitale M, Tzimenatos L, Tunik MG, et al. A Clinical Prediction Rule to Identify Febrile Infants 60 Days and Younger at Low Risk for Serious Bacterial Infections. JAMA Pediatr. 2019 Apr 1;173(4):342–51.
- 9. Shaikh N, Hoberman A, Hum SW, Alberty A, Muniz G, Kurs-Lasky M, et al. Development and Validation of a Calculator for Estimating the Probability of Urinary Tract Infection in Young Febrile Children. JAMA Pediatr. 2018 Jun 1;172(6):550–6.
- 10. Bunting-Early TE, Shaikh N, Woo L, Cooper CS, Figueroa TE. The Need for Improved Detection of Urinary Tract Infections in Young Children. Front Pediatr. 2017;5:24.
- 11. Newman TB, Bernzweig JA, Takayama JI, Finch SA, Wasserman RC, Pantell RH. Urine testing and urinary tract infections in febrile infants seen in office settings: the Pediatric Research in Office Settings' Febrile Infant Study. Arch Pediatr Adolesc Med. 2002 Jan;156(1):44–54.
- 12. Butler CC, O'Brien K, Wootton M, Pickles T, Hood K, Howe R, et al. Empiric antibiotic treatment for urinary tract infection in preschool children: susceptibilities of urine sample isolates. Fam Pract. 2016 Apr;33(2):127–32.
- Hay AD, Sterne JAC, Hood K, Little P, Delaney B, Hollingworth W, et al. Improving the Diagnosis and Treatment of Urinary Tract Infection in Young Children in Primary Care: Results from the DUTY Prospective Diagnostic Cohort Study. Ann Fam Med. 2016 Jul;14(4):325–36.
- 14. Tennant PWG, Murray EJ, Arnold KF, Berrie L, Fox MP, Gadd SC, et al. Use of directed acyclic graphs (DAGs) to identify confounders in applied health research: review and recommendations. International Journal of Epidemiology. 2021 Apr 1;50(2):620–32.
- 15. Greenland S, Pearl J, Robins J. Causal Diagrams for Epidemiologic Research. 1. 1999 Jan;37-48.
- 16. Pearl J. Embracing causality in default reasoning. Artificial Intelligence. 1988 Jun 1;35(2):259–71.
- 17. Korb KB, Nicholson AE. Bayesian Artificial Intelligence. CRC Press; 2010.
- Dempster AP, Laird NM, Rubin DB. Maximum Likelihood from Incomplete Data via the EM Algorithm. Journal of the Royal Statistical Society Series B (Methodological). 1977;39(1):1–38.

- Good IJ. Rational Decisions. In: Kotz S, Johnson NL, editors. Breakthroughs in Statistics: Foundations and Basic Theory [Internet]. New York, NY: Springer; 1992 [cited 2022 Apr 17]. p. 365–77. (Springer Series in Statistics). Available from: https://doi.org/10.1007/978-1-4612-0919-5_24
- 20. Borgonovo E. Sensitivity analysis: An Introduction for the Management Scientist. Cham, Switzerland: Springer; 2017. (International Series in Operations Research and Management Science.).
- 21. Sobol' IM. Global sensitivity indices for nonlinear mathematical models and their Monte Carlo estimates. Mathematics and Computers in Simulation. 2001 Feb 15;55(1):271–80.
- 22. Gerber JS, Hersh AL, Kronman MP, Newland JG, Ross RK, Metjian TA. Development and Application of an Antibiotic Spectrum Index for Benchmarking Antibiotic Selection Patterns Across Hospitals. Infection Control & Hospital Epidemiology. 2017 Aug;38(8):993–7.
- 23. Leung AKC, Wong AHC, Leung AAM, Hon KL. Urinary Tract Infection in Children. Recent Pat Inflamm Allergy Drug Discov. 2019;13(1):2–18.
- 24. Zorc JJ, Kiddoo DA, Shaw KN. Diagnosis and management of pediatric urinary tract infections. Clin Microbiol Rev. 2005 Apr;18(2):417–22.
- 25. Craig JC, Williams GJ, Jones M, Codarini M, Macaskill P, Hayen A, et al. The accuracy of clinical symptoms and signs for the diagnosis of serious bacterial infection in young febrile children: prospective cohort study of 15 781 febrile illnesses. BMJ. 2010 Apr 20;340:c1594.
- 26. Hay AD, Birnie K, Busby J, Delaney B, Downing H, Dudley J, et al. The Diagnosis of Urinary Tract infection in Young children (DUTY): a diagnostic prospective observational study to derive and validate a clinical algorithm for the diagnosis of urinary tract infection in children presenting to primary care with an acute illness. Health Technol Assess. 2016 Jul;20(51):1–294.
- 27. Tosif S, Baker A, Oakley E, Donath S, Babl FE. Contamination rates of different urine collection methods for the diagnosis of urinary tract infections in young children: an observational cohort study. J Paediatr Child Health. 2012 Aug;48(8):659–64.
- 28. Williams TC, Bach CC, Matthiesen NB, Henriksen TB, Gagliardi L. Directed acyclic graphs: a tool for causal studies in paediatrics. Pediatr Res. 2018 Oct;84(4):487–93.
- 29. Leimbach A, Hacker J, Dobrindt U. E. coli as an all-rounder: the thin line between commensalism and pathogenicity. Curr Top Microbiol Immunol. 2013;358:3–32.



In this document we provided all survey questions used for the elicitation of parameters.

Q1. Risk of specimen contamination



Consider the risk of a non-causative organism/s entering the urine specimen during the specimen collection process. In the model (as shown in the above figure), the risk of specimen contamination is influenced by age, sex, presence of diarrhoea, and urine collection method. Assuming the same colonisation status of each child's perineum/ external genitalia (i.e., type and density of organisms), how do the following factors increase or decrease the risk of specimen contamination from the baseline (as specified below)? E.g., x0.3, x2, x10, etc.

1a. Age and sex, assuming clean catch as the method of specimen collection.

Age	Male	Female
>=5yo	1 (baseline)	
2 to 5yo		
6mon to 2yo		
<6mon		

1b. Presence of diarrhoea, assuming clean catch as the method of specimen collection.

Absence	1 (baseline)
Presence	

1c. Urine collection method

Supra aspirate	1 (baseline)
Catheter	
Clean catch	

1d. Any further comments?

Q2. Propensity to UTI progression

Consider a child's risk of progressing to more severe disease manifestations given they have a UTI, e.g., developing kidney infection, or experiencing worsening severity of local or systemic inflammatory response, which can be further broken into two concepts: the **speed of progression**, and the **susceptibility to severity** – illustrated using the diagram below. Please note that these curves are illustrative, not exact.



In the model, both the **speed of progression** and **susceptibility to severity** may be influenced by **age** and **UTI-relevant comorbidity** (such as VUR/anatomical abnormalities of the urinary tract). We now ask a series of questions on these two concept variables. Please provide your min, max, and best guess estimates for each question. Please note that the "min/max" should be plausible lower or upper values, e.g., 95th percentiles, not the extreme recordable value.

2a. Speed of progression

Assuming a baseline speed of progression (as specified below), how do the following factors increase or decrease the baseline? E.g., x0.3, x2, x10, etc.

Age

>=5yo	Speed of progression $= 1$ (baseline)		
Estimate	Min	Max	Best
2 to 5yo			
6mon to 2yo			
<6mon			

UTI-relevant comorbidity

No comorbidity	Speed of progression $= 1$ (baseline)		
Estimate	Min	Max	Best
With comorbidity			

Any further comments on the speed of progression?



2b. Susceptibility to severity

Assuming a baseline susceptibility to severity (as specified below), how do the following factors increase or decrease the baseline? E.g., x0.3, x2, x10, etc.

Age

>=5yo	Susceptibility to severity $= 1$ (baseline)		
Estimate	Min	Max	Best
2 to 5yo			
6mon to 2yo			
<6mon			

UTI-relevant comorbidity

No comorbidity	Susceptibility to severity = 1 (baseline)		
Estimate	Min	Max	Best
With comorbidity			

Any further comments on the susceptibility to severity?

E.g., will the impact be different for different comorbidities, pathogens?



Colonisation of the perineum/ external genitalia by bacteria is assumed to predispose children to urinary tract infection (UTI). In the model, the probability of UTI with each causative pathogen (shown as **causative pathogen** in the above figure) is influenced by **age**, **local colonisation**, and **UTI**relevant comorbidity (such as VUR/anatomical abnormalities of the urinary tract).

3a. Consider the PEA cohort, we enrolled children who presented to the Emergency Department (ED) at Perth Children's Hospital and were managed for presumed UTI (with an antibiotic prescription in the ED and a urine sample sent for laboratory investigation). These patients typically underwent urine dipstick in the ED. What do you estimate the probability (min, max, best guess) of true UTI in this cohort (prior to seeing the laboratory culture result)? Please note that the "min/max" should be plausible lower or upper values, not the extreme recordable value.

	True UTI, in %					
Age	Воу				Girl	
Estimate	Min	Max	Best	Min	Max	Best
>=5yo						
2 to 5yo						
6mon to 2yo						
<6mon						

3b. In the case of an otherwise healthy child with colonisation of the perineum/ external genitalia by all the following three groups of organisms: E.coli, other gram negatives, and gram positives. Note, we refer to gram positives that can potentially cause UTI, such as Enterococcus, rather than gram positives like Staph epidermidis which are unlikely cause UTI.

	Consider the E coli pathogenicity as baseline, could you please indicate the relative pathogenicity of others? E.g., x0.5, x3, etc.	Please comment if different pathogens affect the speed of progression and susceptibility to severity differently? If so,
		how?
E.coli	1 (baseline)	
Other gram negatives		
Gram positives (e.g.,		
Enterococcus)		

Q4. Impact of exiting antibiotic use

4a. For modelling purpose, we have grouped antibiotics into two groups: narrow and broader, could you please review this grouping and suggest if any antibiotic should be grouped differently? Please feel free to add new group/s.

Narrow: Amoxicilin, Amoxicillin + clavulanic acid, Trimethoprim, Trimethoprim + Sulfamethoxazole, Benzylpenicillin, Cefalexin, Cefazolin, Co-trimoxazole, Erythromicin

Broader: Amikacin, Cefepime, Cefotaxime, Ceftazidime, Ceftriaxone, Ciprofloxacin, Colistin, Ertapenem, Gentamicin, Meropenem, Moxifloxacin, Nitrofurantoin, Norfloxacin, Piperacillin + Tazobactam, Tazocin, Tobramycin, Vancomycin

Any further comments?

4b. Given a UTI, the successful detection of the causative pathogen of the UTI in laboratory can be influenced if the patient has been on antibiotic when they came to the ED where the urine sample was taken. Presumably this is largely affected by the antimicrobial susceptibility pattern of the pathogen which can variable by different subgroups, so please consider an average community-acquired case in 2019-2020.

Under the following scenarios, please provide your min, max, and best guess estimates for each question. Please note that the "min/max" should be plausible lower or upper values, not the extreme recordable value. (Please feel free to refer to your experience of treating UTI in adults.)

	Probability of positive culture of E.coli		
Estimate	Min	Max	Best guess
Not on abx			
On narrow abx			
On broader abx			
Pls feel free to add more groups			

Consider a UTI caused by E.coli

	Probability of positive culture of other gram neg		
Estimate	Min	Max	Best guess
Not on abx			
On narrow abx			
On broader abx			

Consider a UTI caused by gram positive bacteria (e.g., Enterococcus)

	Probability of positive culture of gram pos		
Estimate	Min	Max	Best guess
Not on abx			
On narrow abx			
On broader abx			

Any further comments?

Additional file 3: The Expert DAG dictionary

In this document we provided the structure of the Expert DAG v11.1 (Figures C1) and its dictionary (Table C1).



Figure C1. The Expert DAG v11.1, as provided in the main manuscript (Figure 1).

Variable	Description	Parent nodes in the	How affected by parent nodes
name		Expert DAG	
	-	Infection pathway	
UTI: organisms pathogenically invade urinary	Pathogenic organism infecting the urinary tract and causing disease. This is a latent concept describing a UTI in terms of its true pathophysiological state.	Organisms present in the urinary tract (d13), age, comorbidities	As organisms must first enter the urinary system before causing an infection. As age and comorbidities (such as structural urinary system or immune system abnormalities) impact susceptibility to disease and therefore may directly
UTI-localising signs & symptoms (d17)	Patient features that are localised to indicate the urinary tract.	UTI: organisms pathogenically invade urinary tract (d15), age	UTI-specific signs and symptoms such as dysuria can be driven by the presence of a true UTI and age. The influence of age is primarily due to differences in verbal communication of pain and discomfort.
Non-localising signs & symptoms (d16)	Patient features that can indicate UTI but are not specific to a UTI.	UTI: organisms pathogenically invade urinary tract (d15), organisms in bloodstream (d14), age, comorbidities	The observation of non-specific symptoms such as fever can be influenced by age and comorbidities. These signs and symptoms can indicate an increased probability of a true UTI, but to a lesser extent when compared with UTI- specific signs and symptoms. If organisms are present in bloodstream, this can also drive the presentation of non- specific signs & symptoms but may not be discernible from the symptoms of a UTI.
Incompatible signs & symptoms (d18)	Patient features that are unlikely caused by UTI.	Age, comorbidities	Age and comorbidities may influence the probability of incompatible signs & symptoms due to differing susceptibility to other diseases.

Table C1. Variable dictionary of the Expert DAG v11.1.

Variable name	Description	Parent nodes in the Expert DAG	How affected by parent nodes
Organisms in bloodstream (d14)	Pathogenic bacteria in blood stream. This is a latent concept distinct from a diagnosis of bacteraemia. Blood infections seeding the kidneys are rare, yet possible, for example fungal infections in immunosuppressed population. Most positive blood cultures in patients with UTI represent invasion of the blood stream from an infection starting in the urinary tract (urosepsis).	None	NA
Biomarkers (d20)	Laboratory test result providing insight on the clinical picture of the patient. This may include C-reactive protein or a full blood count.	UTI: organisms pathogenically invade urinary tract (d15), age	Biomarkers tested may produce abnormal results driven by the presence or absence of a true UTI. These include inflammatory markers such as CRP and white blood cell count. The influence of age is primarily due to differences in the maturity of the child's immune system thus it's response in the form of elevated biomarkers.
Imaging result (d21)	Radiology imaging results, such as ultrasound, which provide information on potential pathologies of the urinary system.	UTI: organisms pathogenically invade urinary tract (d15), comorbidities	An imaging result, describing abnormal urinary system features suggestive of a UTI for example, is directly influenced by the presence of a UTI. Chronic urinary tract or kidney problems can also be seen via imaging.
Risk of developing complication (d22)	This is a latent concept that collectively describes the risk of progressing to a severe or complicated state of disease.	Age, comorbidities, time to seeking and initiating treatment	Susceptibility to complications of disease is driven by a patient's age and the presence of comorbidities such as urinary system and immune system abnormalities which can cause a more severe UTI. The risk of developing complications is also driven by the time to seeking medical care. For example, a patient may not be assessed by a clinician within an appropriate time and therefore the patient will present to the hospital with a complicated and severe UTI.

Variable name	Description	Parent nodes in the Expert DAG	How affected by parent nodes
Patient progression (d23)	The patient's state after time and clinical management.	UTI: organisms pathogenically invade urinary tract (d15), current & historic antibiotic use (d11), empirically prescribe antibiotics (d5)	A patient's progress is directly influenced by the presence of a true UTI and their response to clinical management such as the prescription of antibiotics.
		Contamination pathway	
Ability to obtain clean catch urine (d24)	Access to a sterile urine specimen (without use of invasive methods). This is a latent term used to describe a patient's seamless or difficult ability to provide a sterile urine specimen free from potential contaminants.	Organisms present on external genitalia (d12), age, continence, sex, circumcision	Age and continence can influence this due to an individual's ability to follow instructions for providing access to clean urine. The presence of bacteria on the external genitalia can influence access to sterile urine as well as sex and circumcision due to the differences in the proximity of bacterial flora to the external opening of the urethral.
Urine collection method (d3)	Method of urine sample collection chosen by the clinician.	Age	The choice of collection method is driven by an ability to produce a clean urine sample and age due to the patient ability to follow instructions required for particular urine specimens.
Collection procedure factors (d25)	Factors relating to collection of the specimen such as number of attempts to collect the specimen, time from cleaning the perineal area to collection of the urine specimen and collection of the specimen in accordance with the specified procedure.	Urine collection method (d3)	Specimen collection factors are driven by the method of urine collection.

Variable name	Description	Parent nodes in the Expert DAG	How affected by parent nodes
Lab procedural factors (d26)	Factors relating to laboratory processing of the urine sample that increase the risk of contamination from the time the urine arrive in the lab to the final reporting. This can include delays in sample processing and refrigeration.	None	NA
Specimen contamination risk (d27)	This is a latent term expressing all factors contributing to contamination.	Organisms present on external genitalia (d12), ability to obtain clean catch urine (d24), urine collection method (d3), collection procedure factors (d25), lab processing factors (d26)	This is driven by all factors that introduce or concentrate non-causative organism from collection to lab processing.
Presence of non-causative organisms in specimen (d28)	Presence and concentration of microorganisms in the urine specimens that are not causing an urinary tract infection.	Organisms present on external genitalia (d12), specimen contamination risk (d27), lab processing factors (d26)	The presence of non-causative organisms is driven by the presence of organisms the external genitalia and the specimen contamination risk. The lab procedural factors (e.g., longer delays) can allow these organisms to proliferate to a higher concentration.
Epithelial cells in specimen (d29)	Epithelial cells entering the urine specimen during collection and reported by the laboratory.	Urine collection method (d3), collection procedure factors (d25)	The presence of epithelial cells in the specimen is driven by urine collection methods and collection procedure factors that cause epithelial cells to enter the urine specimen.
		Overlap	
Background risk factors	Many known risk factors that increase the risk of UTI, complication and contamination, such as age, sex at birth, circumcision, recurrent UTI, immobility, continence, diarrhoea and other comorbidities (a complex story which is not the focus of this paper).	None	NA

Variable name	Description	Parent nodes in the Expert DAG	How affected by parent nodes
Current and historic antibiotic use (d11)	A patient's receipt of antibiotics at the time of presentation or recently prior to assessment. Frequency of historic use is also captured within this node.	Comorbidities	Antibiotic use may be driven by some comorbidities such as congenital urological abnormalities.
Organisms present on external genitalia (d12)	Organism present on external genitalia.	Current & historic antibiotic use (d11), age, sex, circumcision, continence, diarrhoea	Organism presence, type and amount are influenced by a patient's age, sex, whether they are circumcised, their level of continence and current or recent diarrhoea. Current or historic antibiotic use can influence the type and amount of bacteria present.
Organisms present in urinary tract (d13)	An organism entering the urinary tract. This is the precursor to a UTI.	Organisms present on external genitalia (d12), current & historic antibiotic use (d11), age, sex	This is driven by organisms entering the urinary tract via the blood stream during bacteraemia (although rare) or ascending from the external genitalia. A patient's sex and gender can influence this process due to anatomical differences and susceptibility to disease. Historic or current antibiotic treatment may also drive the presence of organisms.
Dipstick results (d19)	Urine analysis/testing available at the point of care.	UTI: organisms pathogenically invade urinary tract (d15), organisms present on external genitalia (d12), age	Dipstick results are directly influenced by the presence or absence of a true UTI, particularly leukocyte esterase and nitrites. Nitrites produced by the colonising gram negative bacteria can be detected from the urine sample even the bacteria is not causing the UTI. The amount of leukocyte esterase can be influenced by age-specific immune response.
Microscopy result (d6)	The presence of white blood cells, red blood cells and bacteria detected by microscopic investigation of the urine sample.	UTI: organisms pathogenically invade urinary tract (d15), presence of non-causative organisms in specimen (d28), send urine to lab (d4)	The presence of bacteria can be due to either the proliferating bacteria that causes a true UTI, or the presence of non-causative organisms in the specimens, or both. The presence of white and red blood cells is typically driven by inflammation or damage caused by a true UTI. Urine microscopy can only be reported if the urine is sent to the lab.

Variable name	Description	Parent nodes in the Expert DAG	How affected by parent nodes
Organism/s cultured from specimen (d7)	Growth of microorganisms from a urine specimen.	UTI: organisms pathogenically invade urinary tract (d15), presence of non-causative organisms in specimen (d28), current & historic antibiotic use (d11), send urine to lab (d4)	The presence, type and amount of organism is driven by the presence of causative or non-causative organisms in the urine specimen, recent antibiotic use, which may change the bacteria grown and their antibiotic susceptibility profiles. Culture can only occur if the decision is made to send the urine to the lab.
		Management pathway	
Initial assessment (d1)	Prior belief of a UTI based on the assessment of the patient's history and background risk factors.	Age, sex, circumcision, continence, diarrhoea, recurrent UTI, and other comorbidities	This belief is driven to a range of factors including a patient's age, sex, circumcision, diarrhoea and other comorbidities (including those that pre-dispose children to recurrent urinary tract infections).
Diagnose suspected UTI (d2)	Diagnosis of a suspected urinary tract infection by the treating clinician.	Initial assessment (d1), non-localising signs & symptoms (d16), UTI- localising signs & symptoms (d17), incompatible signs & symptoms (d18), dipstick results (d19), biomarkers (d20)	Following the initial assessment, the diagnosis made by the treating clinician is formed by their further consultation and investigation including those signs and symptoms that match the picture of a UTI (e.g. dysuria) and those less specific to a UTI (e.g. fever). Symptoms such as rhinorrhoea that are not driven by a true UTI but may be present at the time of clinical assessment can reduce the probability a clinician's suspect the presence of a UTI during the initial assessment. If a dipstick is performed and biomarker results (e.g. CRP) are returned abnormal this may also drive the suspicion of a UTI.
Send urine to lab (d4)	Clinical decision to send the urine specimen to the laboratory for culture.	Diagnose suspected UTI (d2), risk of developing complications (d22)	This is driven by the clinician's suspicion of a UTI and the patient's susceptibility to complications as it is more important to ensure correct management when the risk is higher.
Empirically prescribe antibiotic (d5)	Clinical decision to prescribe (empiric) antibiotics in the ED.	Diagnose suspected UTI (d2), risk of developing complications (d22),	This decision is driven by the diagnosis of a UTI, previous or current antibiotic use as a clinician may choose to change or keep the antibiotic type, and susceptibility to

Variable name	Description	Parent nodes in the Expert DAG	How affected by parent nodes
		current & historic antibiotic use (d11)	complications influences both the decision to prescribe and the type of antibiotic.
Lab report (d8)	Interpretation and reporting of the urine specimen by the laboratory.	Organism/s cultured from specimen (d7), microscopy result (d6), epithelial cells in specimen (d29)	A urine culture report is driven thresholds and reporting rules according to the organism(s) cultured from the specimen, the microscopy results and the presence and quality of epithelial cells in the specimen.
Update clinical diagnoses (d9)	Clinical diagnosis based on updated information.	Diagnose suspected UTI (d2), lab report (d8), biomarkers (d20), imaging result (d21), patient progression (d23)	The diagnosis is influenced by the initial suspicion of a UTI and additional information gained from the laboratory report, biomarker and imaging results and the progress the patient has made with clinical management that may align with a UTI or indicate an alternative illness.
Change, initiate or stop antibiotics (d10)	A clinician's decision to change (including stop) or initiate antibiotics to treat a urinary tract infection based on the receipt of further information	Lab report (d8), update clinical diagnoses (d9), empirically prescribe antibiotics (d5)	The information (if available) driving this decision can include the laboratory report with antibiotic susceptibility results, the clinician's updates clinical diagnoses and whether the patient was empirically prescribes antibiotics.

Additional file 4: List of changes when converting the Expert DAG to the Applied BN

In this document we summarised the major considerations when converting the Expert DAG to the Applied BN. Conversion of the Expert DAG took into consideration: how a particular variable is relevant to the applied BN's purpose; how it could be matched to available data; and how it could help simplify parameterisation or computational workload. This frequently involved simplifications by removing and merging variables, as well expansions by splitting and adding variables. Figure D1 illustrates an example list of decisions made on whether to keep a DAG variable in the BN. We also provided a full list of changes occurred during the conversion from the Expert DAG v11.1 to the Applied BN v2.2 (Table D1).



Figure D1. An example procedure of deciding on whether to keep a DAG variable in the Applied BN.

Changes	Expert DAG	Applied BN
Route of UTI and	Organisms present on external genitalia (d12) and	Acquiring UTI from bloodstream (d14) is rare, thus was dropped
causative	organisms in bloodstream (d14) are two possible routes	for simplification. Grouping d12 and d13 together as local
pathogens	that can lead to organisms present in the urinary tract	colonisation, which approximates a broader area where presence of
	(d13) and subsequently UTI (d15).	organism is relevant (possible to cause UTI). Splitting a general
		organism concept into three specific organism groups (67-9), which
		are the primary predication targets of the model.
Ability to obtain	Explicitly described as a concept that can be influenced	This concept node is removed to simplify the parameterisation
clean catch urine	by age and sex etc. (d24), and subsequently drives urine	need, instead, relevant background factors directly go into urine
	collection methods (d3), contamination risk (d27).	collection methods (b13) and contamination risk (b15) to maintain
		the associations.
Presence of non-	An intermediate step that explicitly describes how (non-	This intermediate node was removed for simplicity, as a result, the
causative organism	causative) colonising organisms may be present in	local colonisations (b7-b9) directly influence the culture results
in specimen	specimen thus isolated (d28).	(b17-b19).
Collection, lab	Described using d25-26 for completeness of the causal	Dropped as considered not highly influential by the domain experts,
procedure factors	story.	as well as with insufficient data for investigation.
Background risk	Simplified as brown text.	Key ones explicitly included as variables/nodes: age group (b1),
factors		UTI-relevant comorbidity (b3), sex (b2) and diarrhoea (b4).
Culture results	Summarised as a single node (d7)	Organism group specific nodes b17-19
Symptoms and	Single node was used to summarise a group of signs and	Specific signs and symptoms are described using separate
signs	symptoms, including those are UTI localising (d17),	nodes/variables with certain interactions among the signs and
	non-localising (d16), and incompatible with UTI (d18).	symptoms (b26-37). Looking for differential effects of different
		signs and symptoms. Observations can be made from the presenting
		patients, entered as input variables when applying the model.
Dipstick	Included as a summary node (d19)	Expanded for differential effects based on data availability (b20-
D: 1		
Biomarkers	Included as a summary node (d20)	Expanded for differential effects based on data availability (b23-
Microscopy result	Included as a summary node (d6)	Expanded for differential effects based on data availability (b16,
T • • • •		
Initial assessment,	d1-2, clinical diagnosis based on evidence available to	Suspected UTI was an inclusion criteria for the PEA study cohort,
diagnosis of	treating doctor at the point of care.	thus these variables were removed. As a result, we are not able to
suspected UTT		explore how such clinical diagnosis was made.

Table D1. Structural changes occurred during our conversion from the Expert DAG v11.1 to the Applied BN v2.2 and their underlying rationale.

Changes	Expert DAG	Applied BN
Send urine to lab	d4	This was an inclusion criteria for the PEA study cohort of suspected
		UTI, thus this variable is removed. As a result, we are not able to
		explore how the urine test decision was made.
Lab report	d8, included to summarise results on microscopy results	Dropped as the microscopic analysis (b16, b22), epithelial cells
	(d6), epithelial cells (d29) and culture results (d7).	(b14), and culture results (b17-19) were explicitly included.
Propensity of UTI	Risk of developing complications (d22)	This variable was first divided into two concepts: susceptibility to
Progression		UTI progression (b5) and current UTI severity (b11). After further
		workshop discussion, b5 and b11 were merged as one variable (for
		structure simplicity) and renamed as current clinical phenotype
		(b11).
Patient outcome of	Described using patient progression (d23), update	All dropped as they are out of the scope of the current application.
the current epsiode	clinical diagnoses (d9), and initiate, stop or change	
	antibiotics (d10).	

Additional file 5: The Applied BN and dictionary

In this document we provided the detailed structure of the Applied BN v2.2 include a high-level structure (Figure E1) and 4 submodels (Figures E2-E5) and the variable dictionary of this model (Table E1).



Figure E1. The high-level structure of the Applied BN v2.2, as provided in the main manuscript (Figure 2, bottom panel).



Figure E2. The local structure of dipstick results submodel (b20-21) with external connections (b1, b7-8, b10).



Figure E3 The local structure of microscopic analy (b23-25) with external connections (b1, b10).



Figure E4 The local structure of microscopic analysis submodel (b16, b22) with external connections (b1, b6, b7-10, b15).



Figure E5 The local structure of signs, symptoms and imaging (b26-b37) with external connections (b1, b3-4, b10, b11). Of note, although the history of diarrhoea (b4) can be a symptom caused by UTI, we modelled it as an important possible cause of UTI therefore excluded from the signs, symptoms and imaging submodel. However, the presence of diarrhoea may lead to reported abdominal pain, thus shown here as an external connection.

	Variahla				Corresponding	
vid	label	Definition	States	Parents	Expert DAG v11	Status
b1	Age group	Age group. All children under 13yo as an inclusion criteria for the PEA Study.	LessThan6Mon, Btw6MonAnd2Yr, Btw2And5Yr, Above5Yr	None	Simplified as brown text	Observable
b2	Sex	Sex at birth.	Female, Male	Age group	Simplified as brown text	Observable
b3	Comorbidity	History of UTI or a history of urinary tract problems, either recorded within their medical notes or reported by their carers in the PEA study survey.	Reported, Unknown	Age group	Simplified as brown text	Observable
b4	Diarrhoea	History of diarrhoea. Although this can be a symptom caused by UTI, we modelled it as an important possible cause of UTI rather than caused by.	Yes, No	Age group	Simplified as brown text	Observable
b6	On abx in ED	On antibiotics upon presentation to ED, if yes, the specified antibiotic was classified as narrow (<=3) or broader (>3) according to published Antibiotic Spectrum Index (Gerber et al., 2017) ¹ .	Narrow, Broader, No	Age group, comorbidity	d11	Observable
b7	E.coli local colonisation	The level of colonisation of the perineum/ external genitalia by E. coli., this is assumed to predispose children to E. coli UTI.	High, Low	Age group, sex, comorbidity, diarrhoea, on abx in ED	d12, d13	Latent
b8	Other gram neg local colonisation	The level of colonisation of the perineum/ external genitalia by non-E. coli gram negative bacteria, this is assumed to predispose children to other gram negative UTI.	High, Low	Age group, sex, comorbidity, diarrhoea, on abx in ED	d12, d13	Latent

Table E1 The variable dictionary of the Applied BN v2.1, and how the variables correspond to the Expert DAG v11.1.

	Variable				Corresponding node/s in the	
vid	label	Definition	States	Parents	Expert DAG v11	Status
b9	Gram pos local colonisation	The level of colonisation of the perineum/ external genitalia by gram positive bacteria, this is assumed to predispose children to gram positive UTI.	High, Low	Age group, sex, comorbidity, diarrhoea, on abx in ED	d12, d13	Latent
b10	Causative pathogen	The pathogenic organism infecting the urinary tract and causing disease.	EColi, OtherGramNeg, GramPos, None	Age group, comorbidity, E.coli local colonisation, other gram neg local colonisation, gram pos local colonisation	d15	Latent
b11	Current clinical phenotype	This was introduced as a summary node of patient presentation phenotypes based on signs and symptoms relevant to UTI.	Type 1, Type 2, Type 3	Age group, comorbidity, causative pathogen	d22	Latent ²
b12	Empiric abx in ED	Empiric antibiotic prescription received during the ED presentation. This is an inclusion criteria for the PEA Study.	Narrow, Broader	On abx in ED, current clinical phenotype, age group	d5	Observable
b13	Urine collection method	Method of urine sample collection chosen by the clinician.	CleanCatch, SupraAsp, Catheter	Age group, comorbidity	d3	Observable
b14	Epithelial cells	Assessment of epithelial cells via microscopic or automated analysis.	Moderate, Low	Age group, sex, urine collection method	d29	Observable
b15	Specimen contamination risk	This latent concept refers to the risk of a non-causative organism/s entering the urine specimen during the specimen collection process.	High, Low	Age group, sex, diarrhea, urine collection method	d27	Latent

	Variable				Corresponding node/s in the	
vid	label	Definition	States	Parents	Expert DAG v11	Status
b16	Bacts under microscopy	Assessment of bacteria via microscopic analysis.	Many, Moderate, Few, NotSeen	Causative pathogen, on abx in ED, specimen contamination risk, E.coli local colonisation, other gram neg local colonisation, gram pos local colonisation	d6	Observable
b17	Growth of E.coli	The isolation of E.coli from the urine specimen.	Positive, Negative	E.coli local colonisation, specimen contamination risk, on abx in ED, causative pathogen	d7	Observable
b18	Growth of other gram neg	The isolation of non-E.coli gram negative bacteria from the urine specimen.	Positive, Negative	Other gram neg local colonisation, specimen contamination risk, on abx in ED, causative pathogen	d7	Observable
b18	Growth of gram pos	The isolation of gram positive bacteria from the urine specimen.	Positive, Negative	Gram pos local colonisation, specimen contamination risk, on abx in ED, causative pathogen	d7	Observable
	Dimeticle	I culto outo octario a data stadio u cuina	Iliala Madaurta	Consections with a new sec		
b20	leuco esterase	dipstick.	Low, NotDetected	group	d19	Observable
b21	Dipstick - nitrite	Nitrite detected on the urine dipstick.	Detected, NotDetected	Causative pathogen, E.coli local colonisation, other gram neg local colonisation	d19	Observable

	Variable				Corresponding node/s in the	
vid	label	Definition	States	Parents	Expert DAG v11	Status
		The assessment of leucocytes level in		~		
b22	Urine - leucocyte	the urine specimen via microscopic analysis.	High, Moderate, Low	Causative pathogen, age group	d6	Observable
			Above18,			
	Blood - WBC		Blw10Ana18, Below10,	Causative pathogen, age		
b23	level	Leukocyte counts in blood.	NotDone	group	d20	Observable
			Above70, Btw15And70			
	Blood - CRP		Below15,	Causative pathogen, age		
b24	level	C-Reactive protein in blood.	NotDone	group	d20	Observable
			Above15,	Causative pathogen, age		
b25	Blood - ANC level	Absolute neutrophil counts in blood.	Btw8And15, Below8, NotDone	group, blood - WBC level	d20	Observable
		Genital pain (or discomfort), dysuria,				
	Urinary tract	and urinary tract relevant discomfort		Causative pathogen,		
b26	discomfort	recorded during ED presentation.	Yes, Unknown	phenotype, age group	d17	Observable
				Causative pathogen,		
	A h dominal	Abdominal nair in madical nates		current clinical		
b27	pain	recorded during ED presentation.	Yes, Unknown	diarrhea	d16, d17	Observable
				Causative pathogen,	,	
1.00		Haematuria in medical notes recorded	X7 T7 1	current clinical	117	01 11
b28	Haematuria	during ED presentation.	Yes, Unknown	pnenotype	d1/	Observable
		Foul smalling uring in modical notes		Causative pathogen,		
b29	Smelly urine	recorded during ED presentation.	Yes, Unknown	phenotype, age group	d17	Observable

	Variable				Corresponding node/s in the	
vid	label	Definition	States	Parents	Expert DAG v11	Status
b30	Ultrasound result	Result of ultrasound investigation. Abnormal ultrasound result was defined if there were features suggestive of pyelonephritis, renal abscess, cystitis or other UTI evidence.	Abnormal, unknown, NotDone	Age group, causative pathogen, comorbidity	d21	Observable
b31	Respiratory symptoms	Respiratory symptoms in medical notes recorded during ED presentation.	Yes, No	Age group	d18	Observable
b32	Parent reported fever	Parent reported fever in medical notes recorded during ED presentation.	Yes, No	Causative pathogen, age group, respiratory symptoms	d16	Observable
b33	Temperature in ED	Temperature (degrees celsius) recorded in ED.	Abv385, Btw375and385, Btw365and375, Below365	Causative pathogen, current clinical phenotype, age group, respiratory symptoms	d16	Observable
b34	Irritable	Irritability in medical notes recorded during ED presentation.	Yes, No	Current clinical phenotype, age group, causative pathogen, temperature in ED	d16	Observable
b35	Lethargy	Lethargy in medical notes recorded during ED presentation.	Yes, No	Causative pathogen, current clinical phenotype, temperature in ED	d16	Observable
b36	Nausea or vomiting	Nausea and/or vomiting in medical notes recorded during ED presentation.	Yes, No	Causative pathogen, current clinical phenotype, age group	d16	Observable

vid	Variable label	Definition	States	Parents	Corresponding node/s in the Expert DAG v11	Status
	Doon onel	Poor oral intoka in madical notas		Current clinical		
	Poor oral	Poor oral intake in medical notes		phenotype, age group,		
b37	intake	recorded during ED presentation.	Yes, No	nausea or vomiting	d16	Observable

¹Narrow: Amoxicilin, Trimethoprim, Benzylpenicillin, Cefalexin, Cefazolin, Erythromicin. Broader: Amoxicillin + Clavulanic acid, Trimethoprim + Sulfamethoxazole, Cotrimoxazole, Amikacin, Cefepime, Cefotaxime, Ceftazidime, Ceftriaxone, Ciprofloxacin, Colistin, Ertapenem, Gentamicin, Meropenem, Moxifloxacin, Nitrofurantoin, Norfloxacin, Piperacillin + Tazobactam, Tazocin, Tobramycin, Vancomycin

² This variable is latent, but was treated uniquely in order to provide a definition of current clinical phenotype that is independent of other latent factors in the model. In particular, a separate clustering was performed (using the EM algorithm) on the signs and symptoms, resulting in a grouping into three types, simply called "Type 1", "Type 2" and "Type 3", "Type 1" being systemic signs and symptoms predominant but mild urinary tract localising symptoms, "Type 2" being urinary tract localising symptoms predominant, and "Type 3" being abdominal pain predominant with minor other symptoms.

Additional file 6: Parameterisation survey responses

In this document we provided a summary of survey responses used to inform the BN parameters.

Q1. Risk of specimen contamination



Consider the risk of a non-causative organism/s entering the urine specimen during the specimen collection process. In the model (as shown in the above figure), the **risk of specimen contamination** is influenced by **age**, **sex**, presence of **diarrhoea**, and **urine collection method**. Assuming *the same* colonisation status of each child's perineum/ external genitalia (i.e., type and density of organisms), how do the following factors increase or decrease the risk of specimen contamination from the baseline (as specified below)? E.g., x0.3, x2, x10, etc. Mean and standard deviation based on survey responses from 8 experts.

Age	Male, mean (sd)	Female, mean (sd)
>=5yo	1 (baseline)	1.8 (1.0)
2 to 5yo	2.2 (0.7)	3.6 (2.0)
6mon to 2yo	3.3 (1.4)	5.2 (3.1)
<6mon	4.2 (2.1)	6.6 (4.0)

1a. Age and sex, assuming clean catch as the method of specimen collection.

1b. Presence of **diarrhoea**, assuming **clean catch** as the method of specimen collection.

Absence	1 (baseline), mean (sd)
Presence	4.1 (1.6)

1c. Urine collection method

Supra aspirate	1 (baseline), mean (sd)
Catheter	2.3 (1.2)
Clean catch	6.8 (5.4)

Collated comments

2-5 year old age group above would also be influenced by whether the child is toilet trained or not as yet.

the organisms introduced relate more to how clean a catch it is...if that makes any sense. Older kids pass urine straight into the cup, can do mid-stream when older again. A small child will be wiped clean but then gets progressively dirty waiting for the catch and often the urine sprays everywhere, has touched skin on way through.

If female with diarrhoea is at highest risk.

Could consider circumcision in boys reducing the contamination rates

Q2. Propensity to UTI progression

Consider a child's risk of progressing to more severe disease manifestations given they have a UTI, e.g., developing kidney infection, or experiencing worsening severity of local or systemic inflammatory response, which can be further broken into two concepts: the **speed of progression**, and the **susceptibility to severity** – illustrated using the diagram below. Please note that these curves are illustrative, not exact.



In the model, both the **speed of progression** and **susceptibility to severity** may be influenced by **age** and **UTI-relevant comorbidity** (such as VUR/anatomical abnormalities of the urinary tract). We now ask a series of questions on these two concept variables. Please provide your min, max, and best guess estimates for each question. Please note that the "min/max" should be plausible lower or upper values, e.g., 95th percentiles, not the extreme recordable value. Mean and standard deviation based on survey responses from 8 experts.

2a. Speed of progression

Assuming a baseline speed of progression (as specified below), how do the following factors increase or decrease the baseline? E.g., x0.3, x2, x10, etc.

	-					
	>=5yo	Speed of progression = 1 (baseline)				
	Estimate	Min, mean	Max, mean	Best, mean (sd)		
	2 to 5yo	0.9	3.9	1.8 (0.7)		
	6mon to 2yo	1.2	4.9	3.2 (1.8)		
	<6mon	1.8	7.4	5.5 (3.6)		

UTI-relevant comorbidity

No comorbidity	Speed of progression = 1 (baseline)		
Estimate	Min, mean	Max, mean	Best, mean (sd)

Age

 medRxiv preprint doi: https://doi.org/10.1101/2022.04.18.22273959; this version posted April 18, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

 It is made available under a CC-BY-NC-ND 4.0 International license .

 With comorbidity
 1.3

 6.1
 3.3 (2.0)

2b. Susceptibility to severity

Assuming a baseline susceptibility to severity (as specified below), how do the following factors increase or decrease the baseline? E.g., x0.3, x2, x10, etc.

Age

>=5yo	Susceptibility to severity = 1 (baseline)			
Estimate	Min, mean	Max, mean	Best, mean (sd)	
2 to 5yo	1.0	4.1	1.7 (0.8)	
6mon to 2yo	1.2	4.8	3.0 (2.0)	
<6mon	1.7	6.3	5.1 (3.9)	

UTI-relevant comorbidity

No comorbidity	Susceptibility to severity = 1 (baseline)			
Estimate	Min, mean	Max, mean	Best, mean (sd)	
With comorbidity	1.4	6.3	3.6 (1.8)	

Collated comments

I would categorise age <1mo as much higher risk than 1-5 months. Many congenital renal abnormalities would not necessarily predispose to a more rapid progression (eg VUR Grade 1-III), but some would definitely increase risk of more rapid progression to disease (eg posterior urethral valves in a child <6mo)

(Speed of progression) Pathogens particularly virulent e.g K1 E coli, presence of comorbidity and a foreign body may play a role such as the presence of a stent

(Susceptibitlity to severity) Just thinking of some patients that don't follow these trends – not sure my clinician knowledge is that good when you think about all the patients that don't fit the text book!!

(Speed of progression) Will be affected by immunosuppression.

Is impacted by congenital bladder and renal tract anomalies. However, this is hard to quantify on a baseline of an increased frequency of infections, many of which do not progress past cystitis.

(Susceptibitlity to severity) This is on a low baseline risk.

Different comorbidities likely to affect speed of progression.

Lumping co-morbidities in one may be misleading – mild degree of VUR is unlikely to make a difference, but severe VUR will

Severe and progression I think are likely to be interrelated

Q3. Causative pathogen for UTI



Colonisation of the perineum/ external genitalia by bacteria is assumed to predispose children to urinary tract infection (UTI). In the model, the probability of UTI with each causative pathogen (shown as **causative pathogen** in the above figure) is influenced by **age**, **local colonisation**, and **UTI-relevant comorbidity** (such as VUR/anatomical abnormalities of the urinary tract).

3a. Consider the PEA cohort, we enrolled children who presented to the Emergency Department (ED) at Perth Children's Hospital and were managed for presumed UTI (with an antibiotic prescription in the ED and a urine sample sent for laboratory investigation). These patients typically underwent urine dipstick in the ED. What do you estimate <u>the probability</u> (min, max, best guess) of true UTI in this cohort (prior to seeing the laboratory culture result)? Please note that the "min/max" should be plausible lower or upper values, not the extreme recordable value. Mean and standard deviation based on survey responses from 8 experts.

	True UTI, in %					
Age	Воу		Girl			
	Min,	Max,	Best, mean	Min,	Max,	Best, mean
Estimate	mean	mean	(sd)	mean	mean	(sd)
>=5yo	59	83	77 (30)	58	88	76 (19)
2 to 5yo	54	92	70 (20)	53	92	73 (12)
6mon to 2yo	54	91	61 (28)	52	89	63 (24)
<6mon	54	86	62 (29)	51	84	63 (29)

Collated comments

Even with a culture positive, sometimes the dipstick/microscopy/clinical interpretation is suboptimal. In see a lot of children with recurrent UTI in clinic, in maybe 20% of these referrals the children are mostly having misdiagnosed infections (i.e. contamination labelled as UTI). Colonisation is a urine consistent with UTI, but no symptoms and this is VERY hard to model, and poorly understood by paediatricians (now widely accepted in adult medicine).

The probability of a positive culture after Rx for UTI in ED will be inflated by contamination. I am assuming that that a prescription would be driven by an abnormal UA, so this question is what is the likelihood of a true UTI in the presence of an abnormal urinalysis.

The sensitivity and specificity of different components of urinalysis vary which makes estimating these numbers difficulty

Although tradition suggests that sensitivity and specificity varies by age, this is in my mind, overstated and that it is remains a good test in young children

medRxiv preprint doi: https://doi.org/10.1101/2022.04.18.22273959; this version posted April 18, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license, 3b. In the case of an otherwise healthy child with colonisation of the perineum/ external genitalia by all the following three groups of organisms: E.coli, other gram negatives, and gram positives. Note, we refer to gram positives that can potentially cause UTI, such as Enterococcus, rather than gram positives like Staph epidermidis which are unlikely cause UTI. Mean and standard deviation based on survey responses from 8 experts.

	Consider the E coli pathogenicity as baseline, could you please indicate the relative pathogenicity of others? E.g., x0.5, x3, etc., mean (sd)	Please comment if different pathogens affect the speed of progression and susceptibility to severity differently? If so, how?
E.coli	1 (baseline)	
Other gram negatives	1.35 (0.53)	
Gram positives (e.g.,	0.98 (0.91)	
Enterococcus)		

Collated comments

GramPos: Might be less than gram negatives, but do not have a good feel for this.

OtherGramNeg: Variable speed and severity (likely potentially lower, dependent on bug e.g., Kleb similar but Serratia lower)

GramPos: Low speed and severity

OtherGramNeg: Pseudomonas 2, Resistant gram negatives e.g ESBL 3; Particularly in a younger child, Given less likely to have early effective treatment and more challenging to treat

GramPos: Less severe and progressive

OtherGramNeg: Potentially more rapid spread with other gram negatives in the context of underlying renal anomalies and particularly with those with a stent in situ (biofilm formation, eg with organisms such as Pseudomonas aeruginosa).

GramPos: Generally less likely to cause disseminated infection.

E coli more frequently coloniseds, but the pathogenicity of this compared with other Enterobactericeae (e.g. Klebsiella, Enterobacter) is the same. Enterococci are the weeds of the urinary tract – in regard to pathogenicity, speed and severity

Q4. Impact of exiting antibiotic use

4a. For modelling purpose, we have grouped antibiotics into two groups: narrow and broader, could you please review this grouping and suggest if any antibiotic should be grouped differently? Please feel free to add new group/s.

Narrow: Amoxicilin, Amoxicillin + clavulanic acid, Trimethoprim, Trimethoprim + Sulfamethoxazole, Benzylpenicillin, Cefalexin, Cefazolin, Co-trimoxazole, Erythromicin

Broader: Amikacin, Cefepime, Cefotaxime, Ceftazidime, Ceftriaxone, Ciprofloxacin, Colistin, Ertapenem, Gentamicin, Meropenem, Moxifloxacin, Nitrofurantoin, Norfloxacin, Piperacillin + Tazobactam, Tazocin, Tobramycin, Vancomycin

Comment: From only one expert.

Please see attached for a published list of antibiotics with their proposed "spectrum score". Thus, I'd suggest you compare your below two groupings to ensure that all those in the "narrow" group have spectrum scores lower than all those in the "broader" group. Based on this you may need to move a few antibiotics between the two groups to ensure they are grouped appropriately (eg

medRxiv preprint doi: https://doi.org/10.1101/2022.04.18.22273959; this version posted April 18, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND-4.0 International license . Amoxicillin + clavulanic acid and Co-trimoxazole probably need to be in the "broader" group). This would have the additional benefit of being able to reference your classification.

4b. Given a UTI, the successful detection of the causative pathogen of the UTI in laboratory can be influenced if the patient has been on antibiotic when they came to the ED where the urine sample was taken. Presumably this is largely affected by the antimicrobial susceptibility pattern of the pathogen which can variable by different subgroups, so please consider an average community-acquired case in 2019-2020.

Under the following scenarios, please provide your min, max, and best guess estimates for each question. Please note that the "min/max" should be plausible lower or upper values, not the extreme recordable value. (Please feel free to refer to your experience of treating UTI in adults.) Response received from only one expert.

Consider a UTI caused by E.coli

	Probability of positive culture of E.coli			
Estimate	Min	Max	Best guess	
Not on abx	50	100	80	
On narrow abx	20	50	30	
On broader abx	10	30	20	
Pls feel free to				
add more groups				

Consider a UTI caused by other gram negative bacteria

	Probability of positive culture of other gram neg			
Estimate	Min	Max	Best guess	
Not on abx	50	100	80	
On narrow abx	20	50	30	
On broader abx	10	30	20	

Consider a UTI caused by gram positive bacteria (e.g., Enterococcus)

	Probability of positive culture of gram pos			
Estimate	Min	Max	Best guess	
Not on abx	50	100	80	
On narrow abx	20	50	30	
On broader abx	10	30	20	

Comment:

In the absence of any data to support my estimates, my guesses are the same for E.coli/gram neg/gram positives.